Editorial: Lurbinectedin for neuroendocrine tumors
A new editorial paper was published in Oncoscience, titled "Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer."
Oct 6, 2023
0
47
A new editorial paper was published in Oncoscience, titled "Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer."
Oct 6, 2023
0
47
More than 1.9 million new colorectal cancer (including anus) cases and 935,000 deaths were estimated to occur worldwide in 2020, representing about one in 10 cancer cases and deaths. Overall, colorectal ranks third in terms ...
Oct 3, 2023
0
38
A team of researchers at the Medical University of Vienna has discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of a specific protein called P-glycoprotein (P-gp). This discovery ...
Oct 2, 2023
0
6
Researchers have found a protein to block the growth of cancer stem-like cells as a possible treatment for pancreatic cancer.
Sep 26, 2023
0
58
Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study ...
Sep 21, 2023
0
16
Liver cancer is one of the most prevalent and deadly types of cancer worldwide. Most patients are diagnosed at an advanced stage, which leaves them with few treatment options. Unfortunately, the first-line drugs used in advanced ...
Sep 20, 2023
0
1
The risk of death from breast cancer is 43% higher for women who had at least one treatment interval longer than the recommended treatment timeframes, according to new research.
Sep 18, 2023
0
1
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Sep 14, 2023
0
66
A standard chemotherapy drug injures surrounding non-cancer cells, which can then awaken dormant cancer cells and promotes cancer growth, according to a new study publishing September 12 in the open access journal PLoS Biology ...
Sep 12, 2023
0
81
Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented from ...
Sep 11, 2023
0
19